What records are connected here?
- Evidence lanes
- 2
- Source years
- 4
- Drugs@FDA applications
- 0
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Not FDA-approved2,3Evidence: Large human trialsNot a peptideHormones
Also called Ibutamoren, Ibutamoren mesylate, MK-06771
Not a peptide: a small molecule often looked up alongside peptides.
MK-677, also called ibutamoren, is a small synthetic compound, not a peptide, that researchers describe as a nonpeptide growth hormone secretagogue: a drug meant to make the body release more growth hormone.1,7 FDA has placed ibutamoren mesylate in category 2 of its compounding lists, for substances that may present significant safety risks, because of the potential for congestive heart failure in certain patients.2 In a randomized trial of 563 people with Alzheimer disease it raised IGF-1 levels but did not slow the disease. No FDA approval is reported in the sources reviewed here.2,5
| Substance type | Not a peptide. A 1998 study describes MK-0677 as a nonpeptide growth hormone secretagogue, and FDA’s substance registry records ibutamoren mesylate as a chemical compound rather than a protein.1,7 |
|---|---|
| What it is | A synthetic small-molecule growth hormone secretagogue, recorded by FDA’s substance registry as ibutamoren mesylate and also called MK-677 and MK-0677.1,7 |
| FDA status | No FDA approval is reported in the sources reviewed here. FDA lists ibutamoren mesylate in category 2 of both of its interim compounding policies, for substances that may present significant safety risks, and its advisory committee voted 13 to 1 in 2024 against adding it to the compounding list.2,3 |
| Human evidence | Randomized trials in older adults: a 12-month trial in 563 people with Alzheimer disease found no effect on the disease, and a hip-fracture trial was stopped early over heart failure.5,6 |
| Evidence strength | Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned |
MK-677 is a lab-made compound, not a peptide. A 1998 study describes it as a nonpeptide growth hormone secretagogue, and FDA’s substance registry records it as ibutamoren mesylate, a chemical compound also known as MK-0677.1,7
Its registry record lists the names ibutamoren mesylate, MK-0677 and MK-677.1
It is designed to prompt the release of growth hormone. In rats, MK-0677 activated nerve cells in the arcuate nucleus of the hypothalamus that help control growth hormone release, according to the 1998 study.7
In the 2008 Alzheimer disease trial it raised blood levels of insulin-like growth factor 1 (IGF-1) by about 60% at 6 weeks and 73% at 12 months.5
A randomized, double-blind trial enrolled 563 people with mild to moderate Alzheimer disease for 12 months. MK-677 raised IGF-1 levels but made no significant difference to any measure of the disease, and the authors concluded it was ineffective at slowing its progression.5
A randomized, placebo-controlled trial in 123 older adults recovering from hip fracture found faster walking speed but no improvement in most other measures of physical function. It was terminated early because of a safety signal of congestive heart failure in a limited number of patients.6
The authors of the hip-fracture trial concluded that MK-0677 had an unfavorable safety profile in that population.6
Evidence-strength label: Large randomized human trials. How this label is assigned
None of the sources reviewed here reports an approval of MK-677 by FDA.1,2
FDA’s compounding safety-risk page, current as of April 22, 2026, lists ibutamoren mesylate in category 2 under both interim compounding policies: for pharmacies (section 503A) since September 29, 2023, and for outsourcing facilities (section 503B) since December 29, 2022.2
FDA states that it poses significant safety risks because of the potential for congestive heart failure in certain patients, and cites a randomized, placebo-controlled hip-fracture trial that was terminated early because of a potential safety signal of congestive heart failure.2
A Federal Register notice announced the October 29, 2024 meeting of FDA’s Pharmacy Compounding Advisory Committee, which considered ibutamoren mesylate for the 503A bulks list for uses including growth hormone deficiency, osteoporosis, hip fracture, sarcopenia, obesity and Alzheimer disease. FDA proposed that it not be included, and the committee voted 13 to 1 against placing it on the list, according to the minutes.3,4
According to the minutes, several members said the evidence presented did not support effectiveness and safety, and raised concerns about reported fluid retention, congestive heart failure and high blood sugar.3
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. MK-677 is not among them.8,9
Whether raising growth hormone and IGF-1 with MK-677 benefits any condition: the largest trial reviewed here found no effect on Alzheimer disease.5
How large the heart-failure risk is and who is most at risk; FDA describes the risk in certain patients, and the hip-fracture trial saw it in a limited number of patients.2,6
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for MK-677: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for MK-677 are a bounded selection, not every registration or paper about MK-677. For the years before MK-677 was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list MK-677 as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name MK-677 in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
No FDA approval reported; on FDA’s compounding safety-risk list (category 2). A randomized trial of 563 people with Alzheimer disease found no effect, and a hip-fracture trial was stopped early over heart failure. MK-677 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
No FDA approval reported; on FDA’s compounding safety-risk list (category 2). A randomized trial of 563 people with Alzheimer disease found no effect, and a hip-fracture trial was stopped early over heart failure. MK-677 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date January 27, 2026
LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report.↗Added to PeptideScanner November 16, 2026Literature metadata · added November 16, 2026
LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report.↗Source date January 27, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT05364684↗Source date January 6, 2026Literature metadata · added November 16, 2026
Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamoren.↗Source date October 20, 2022PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
2 of 2 selected trial records include at least one phase value; 2 of 2 include a status value in the retained structured contract.
4 of 4 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT00395291 at 2026-11-16T17:28:23.215Z. Its registry update date was 2017-02-20, and PeptideScanner's reviewed identity mapping was mk-677.
PeptideScanner retained ClinicalTrials.gov record NCT05364684 at 2026-11-16T17:28:23.215Z. Its registry update date was 2026-01-06, and PeptideScanner's reviewed identity mapping was mk-677.
PubMed lists PMID 31964466 in BMB reports as Journal Article, with publication-date metadata of 2020-03 (month precision). PeptideScanner associated the retained record with the identity slug mk-677. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
4 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Selected records span February 20, 2017 to January 27, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 36303408 in Experimental physiology as Case Reports, Research Support, Non-U.S. Gov't, Journal Article, with publication-date metadata of 2022-11-16 (day precision). PeptideScanner associated the retained record with the identity slug mk-677. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05364684 at 2026-11-16T17:28:23.215Z. Its registry update date was 2026-01-06, and PeptideScanner's reviewed identity mapping was mk-677.↗
Literature metadata
PubMed lists PMID 34737341 in Nature communications as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-11-04 (day precision). PeptideScanner associated the retained record with the identity slug mk-677. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 34542924 in Rapid communications in mass spectrometry : RCM as Journal Article, with publication-date metadata of 2021-12-15 (day precision). PeptideScanner associated the retained record with the identity slug mk-677. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 31964466 in BMB reports as Journal Article, with publication-date metadata of 2020-03 (month precision). PeptideScanner associated the retained record with the identity slug mk-677. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00395291 at 2026-11-16T17:28:23.215Z. Its registry update date was 2017-02-20, and PeptideScanner's reviewed identity mapping was mk-677.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
Federal Register via GovInfo · Official source · Source checked August 21, 2026
Neurology · Official source · Source checked November 16, 2026
Archives of Gerontology and Geriatrics · Official source · Source checked November 16, 2026
Journal of Neuroendocrinology · Official source · Source checked November 16, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026